Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-Year outcome

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 248, Issue 7, 2010, Pages 937-941

  Ruiz Moreno, Jose M ^a,b,d   Montero, Javier A ^b,c  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^b Vitreo Retinal Unit ^*  (Spain)

^c HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^d Facultad de Medicina   (Spain)

Author keywords

Bevacizumab; Choroidal neovascularization; High myopia; Intravitreal injection

Indexed keywords

BEVACIZUMAB; VERTEPORFIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; EYE DISEASE; FEMALE; HIGH MYOPIA; HUMAN; MALE; OFF LABEL DRUG USE; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC DISEASE; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAOCULAR; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY; YOUNG ADULT;

EID: 77955652770     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-010-1340-y     Document Type: Article

References (27)

1. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ (1996) Etiology of choroidal neovascularization in young patients. Ophthalmology 103:1241-1244
2. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS (2007) Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 91:157-160
3. Tewari A, Dhalla MS, Apte RS (2006) Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 26:1093-1094
4. Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M, Oshima Y, Kusaka S, Tano Y (2007) Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 91:161-165 (Pubitemid 46202863)
5. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Ares S, Lopez- Lopez F, Rodriguez M, Fernandez M (2009) Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye 23:334-338
6. Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA (2005) Bevacizumab suppresses choroidal neovascularisat ioncaused by pathological myopia. Br J Ophthalmol 89:1368-1370
7. Mandal S, Venkatesh P, Sampangi R, Garg S (2007) Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 17:620-626 (Pubitemid 47605773)
8. Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM Jr (2006) Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 26:960-963 (Pubitemid 44547453)
9. Chan WM, Lai TY, Liu DT, Lam DS (2007) Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 114:2190-2196
10. Arias L, Planas N, Prades S, Caminal JM, Rubio M, Pujol O, Roca G (2008) Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol 92:1035-1039
11. Wu PC, Chen YJ (2009) Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye
12. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S (2009) Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 93:448-451
13. Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, Tano Y (2009) Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 147(94-100):e101
14. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB (2009) Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 147(84-93):e81
15. Chan WM, Lai TY, Liu DT, Lam DS (2009) Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 93:150-154
16. Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS (2006) Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 141:456-462
17. Bennett MD, Yee W (2007) Pegaptanib for myopic choroidal neovascularization in a young patient. Graefes Arch Clin Exp Ophthalmol 245:903-905
18. Silva RM, Ruiz-Moreno JM, Nascimento J, Carneiro A, Rosa P, Barbosaa A, Carvalheira F, Abreu JR, Cunha-Vaz JG (2008) Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 28:1117-1123
19. Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A (2009) Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 247:311-318
20. Figurska M, Stankiewicz A (2008) Anty-VEGF therapy in the treatment of myopic macular choroidal neovascularization-cases report. Klin Oczna 110:387-391
21. Ruiz-Moreno JM, Amat P, Montero JA, Lugo F (2008) Photodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years' outcome. Br J Ophthalmol 92:792-794
22. Ikuno Y, Nagai Y, Matsuda S, Arisawa A, Sho K, Oshita T, Takahashi K, Uchihori Y, Gomi F (2009) Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 149:140-146
23. Krebs I, Binder S, Stolba U, Glittenberg C, Brannath W, Goll A (2005) Choroidal neovascularization in pathologic myopia: threeyear results after photodynamic therapy. Am J Ophthalmol 140:416-425
24. Ruiz-Moreno JM, Montero JA (2003) Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes. Br J Ophthalmol 87:856-859
25. Baba T, Kubota-Taniai M, Kitahashi M, Okada K, Mitamura Y, Yamamoto S (2009) Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularization. Br J Ophthalmol. doi:10.1136/bjo.2009.166025
26. Ruiz-Moreno JM, Montero JA (2002) Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes. Eur J Ophthalmol 12:117-122
27. Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 19:361-372